Tyche Industries Limited , a prominent player in the pharmaceutical sector, has announced significant changes to its leadership structure following the company's 27th Annual General Meeting (AGM) held on September 30, 2025. The reshuffling marks a new chapter in the company's governance and strategic direction.

Key Leadership Changes

The shareholders approved several pivotal appointments and changes in designations:

1. New Managing Director: Sandeep Gokaraju has been appointed as the Managing Director for a five-year term, effective September 5, 2025. Mr. Gokaraju, a qualified engineer with a B.Tech in Chemical Engineering and an MBA, brings over 12 years of experience in pharmaceutical marketing, product development, and overall management to his new role.

2. Executive Director Appointments:

   • G Ganesh Kumar, previously the Chairman and Managing Director, has transitioned to the role of Executive Director.
   • Satya Srinivas Uppalapati joins the board as an Executive Director, bringing more than 30 years of experience in pharmaceutical marketing and product development.

3. Independent Directors:

   • Srinivas Gelli's designation has changed from Non-Executive Director to Non-Executive Independent Director.
   • Penumatsa Vijaya Lakshmi has been re-appointed as an Independent Director for a second five-year term.

Board Composition and Expertise

The newly structured board brings a diverse set of skills and experiences:

• Sandeep Gokaraju and G Ganesh Kumar, who are brothers, will lead the company's operations and strategy. G Ganesh Kumar holds a Master of Business degree from the USA and has over 20 years of experience in production and administration.
• Satya Srinivas Uppalapati, a B.Tech in Mechanical Engineering, adds substantial expertise in pharmaceutical marketing and product development.
• Srinivas Gelli, a Chartered Accountant and Cost Accountant, brings over 20 years of experience in accounting and finance.
• Penumatsa Vijaya Lakshmi, with an MBA, contributes 14 years of experience in accounting and finance.

Additional AGM Approvals

The AGM also saw the approval of other significant matters:

• A dividend of 30% (Rs. 3.00 per share) was declared for the financial year ended March 31, 2025.
• Mrs. D. Renuka, a practicing Company Secretary, was appointed as the Secretarial Auditor for a term of five consecutive financial years from 2025-26 to 2029-30.
• The remuneration for the Cost Auditor, Mr. Sativada Venkat Rao, for the financial year 2025-26 was approved.

Governance and Compliance

Tyche Industries has ensured compliance with SEBI regulations and corporate governance norms. The AGM was conducted through video conferencing, adhering to the guidelines set by the Ministry of Corporate Affairs and SEBI in light of the ongoing global situation.

The strategic leadership restructuring reflects Tyche Industries' commitment to leveraging diverse expertise for future growth and maintaining strong corporate governance practices. The blend of family leadership and independent directors aims to balance continuity with fresh perspectives in the company's decision-making process.

Tyche Industries Limited , a prominent player in the pharmaceutical sector, has announced significant leadership changes and key decisions following its Board of Directors meeting held on September 5, 2025. The company has set the stage for its 27th Annual General Meeting (AGM) and revealed a series of strategic appointments that are poised to shape its future direction.

Leadership Restructuring

In a major organizational shift, Mr. G Ganesh Kumar has stepped down from his position as Chairman cum Managing Director, effective September 5, 2025. However, he will continue to serve the company as an Executive Director, leveraging his extensive experience in production, administration, and marketing.

Taking the helm, Mr. Sandeep Gokaraju has been appointed as the new Chairman cum Managing Director, subject to shareholder approval. With over 12 years of industry experience, Mr. Gokaraju brings expertise in pharmaceutical product marketing, new product development, finance, and regulatory affairs to his new role.

New Appointments and Designations

The Board has made several other key appointments:

• Mr. Satya Srinivas Uppalapati has been named as an additional Executive Director, bringing over 30 years of experience in pharmaceutical marketing and product development.
• Mr. Srinivas Gelli's role has been elevated from Non-Executive Director to Non-Executive Independent Director, adding depth to the company's governance structure.
• Mrs. Penumatsa Vijaya Lakshmi has been recommended for re-appointment as an Independent Director for a second five-year term, subject to shareholder approval.

27th Annual General Meeting Details

Tyche Industries has scheduled its 27th AGM for September 30, 2025, to be conducted via video conferencing. Key details include:

Other Important Decisions

The Board has also:

• Adopted the Board's Report and Management Discussion & Analysis Report for the financial year 2024-25.
• Appointed Mrs. D Renuka as the scrutinizer for e-voting.
• Recommended ratification of Cost-Auditors' remuneration.
• Approved opening a dividend account with IDBI Bank Limited.

These changes mark a significant transition for Tyche Industries Limited as it positions itself for future growth and enhanced corporate governance. Shareholders will have the opportunity to vote on these key appointments and decisions during the upcoming AGM.

The company's focus on strengthening its leadership team and maintaining transparency through e-voting and proper disclosures demonstrates its commitment to long-term value creation for all stakeholders.